RxDoctor Payments Data

Bradley Holland, MD

Urology · Springfield, ILNPI 1578910741

Payments from drug & device makers

$4,952in general payments, 2019–2025

Across 140 payments — averaging $35.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Valencia Technologies Corporation$1K
  • Urogen Pharma, Inc.$357
  • Cook Medical LLC$300
  • Procept Biorobotics Corporation$233
  • Astellas Pharma US Inc$194
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$93919%
  • Food & beverage$3,61973%
  • Education$3958%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,952 in reported general payments places this provider in the 65th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$163,394
Medicare patients
671
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron399$225,234
GemtesaVibegron121$74,044
Tamsulosin Hcl871$9,578
Mirabegron ErMirabegron12$4,525
Potassium Citrate ErPotassium Citrate42$4,389
Finasteride442$3,973
Solifenacin Succinate86$3,721
Estradiol37$2,436
Testosterone12$1,503
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,293
Tolterodine Tartrate16$1,172
Oxybutynin Chloride ErOxybutynin Chloride77$853
Dutasteride39$696
Methenamine Hippurate15$613
NitrofurantoinNitrofurantoin Macrocrystal20$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$194$225,234399 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 550 urology providers in Illinois.

Other urology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →